^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    5T4-targeted antibody-drug conjugate

    Related drugs:
    Apply
    Study of ASN004 in Patients With Advanced Solid Tumors (NCT04410224)
    Phase 1
    Kirilys Therapeutics Inc.
    Active, not recruiting
    Last update posted :
    02/23/2024
    Initiation :
    04/08/2022
    Primary completion :
    06/30/2024
    Completion :
    09/30/2024
    TPBG
    |
    TPBG expression
    |
    ASN004
    Naptumomab Estafenatox in Combination With Durvalumab in Subjects With Selected Advanced or Metastatic Solid Tumors (NCT03983954)
    Phase 1
    NeoTX Therapeutics Ltd.
    Active, not recruiting
    Last update posted :
    02/22/2024
    Initiation :
    10/10/2019
    Primary completion :
    10/01/2026
    Completion :
    10/01/2026
    HER-2 • ER • TPBG
    |
    HER-2 negative
    |
    Imfinzi (durvalumab) • Gazyva (obinutuzumab) • Anyara (naptumomab estafenatox)
    ABR-217620/Naptumomab Estafenatox With Interferon-alpha (IFN-alpha) Compared to IFN-alpha Alone in Patients With Advanced Renal Cell Carcinoma (NCT00420888)
    Phase 2/3
    Active Biotech AB
    Completed
    Last update posted :
    07/22/2015
    Initiation :
    01/01/2007
    Primary completion :
    01/01/2013
    Completion :
    01/01/2013
    IFNA1
    |
    Anyara (naptumomab estafenatox)